1,088 reports of this reaction
3.7% of all LIFITEGRAST reports
#7 most reported adverse reaction
DYSGEUSIA is the #7 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 1,088 FDA adverse event reports linking LIFITEGRAST to DYSGEUSIA. This represents approximately 3.7% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience dysgeusia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSGEUSIA is moderately reported among LIFITEGRAST users, representing a notable but not dominant share of adverse events.
In addition to dysgeusia, the following adverse reactions have been reported for LIFITEGRAST:
The following drugs have also been linked to dysgeusia in FDA adverse event reports:
DYSGEUSIA has been reported as an adverse event in 1,088 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSGEUSIA accounts for approximately 3.7% of all adverse event reports for LIFITEGRAST, making it a notable side effect.
If you experience dysgeusia while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.